Serodiagnosis of amoebic abscess: a retrospective diagnostic accuracy study of kits marketed in Europe.

Fiche publication

Date publication

octobre 2025

Journal

Journal of clinical microbiology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMIOT Clotilde

Tous les auteurs :
Prétot E, Brenier-Pinchart M-P, Tirard-Collet P, Gabriel F, Touafek F, Marteau A, Delcey L, Amiot C, Dupont D, Fricker-Hidalgo H, Sokol H, Moreno-Sabater A, Grenouillet F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41117545

Résumé

Amoebiasis is a cosmopolitan parasitic disease caused by . The most lethal form is extra-intestinal amoebiasis, mainly manifesting as liver abscesses. Diagnosis is based on clinical, radiological, and biological tests. However, there are currently few serology reagents still available on the European market for diagnosis, and comparative studies of existing reagents are required. We evaluated the performances of the four currently available reagents, either as standalone tests or in combination. Two enzyme-linked immunosorbent assays (ELISAs) for the detection of IgG were assessed: one manufactured by Bordier and the other by NovaTec. Additionally, an indirect hemagglutination technique, ELI.H.A , and a latex particle agglutination technique, ELITex Bicolor , both produced by ELITech Microbio, were evaluated. A total of 442 serum samples were selected from a shared centralized biobank of seven university hospitals in France. The samples included 79 from patients with amoebic abscess, 13 with amoebic colitis, and 350 from healthy donors and patients with parasitic and non-parasitic diseases, especially liver disease and immune dysfunction. The sensitivity of the four kits ranged from 87.3% to 97.5%, while their specificity ranged from 78.3% to 98.6%. Bordier ELISA demonstrated the highest sensitivity, while ELITex Bicolor latex reagent exhibited the highest specificity. The combination of Bordier ELISA and/or ELI.H.A for screening, combined with ELITex Bicolor for confirmation of positive screening results, yielded the most optimal performance. This study highlights the benefits of large comparative studies of commercial assays to guide clinical microbiologists in their choices.